Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known. The investigators will explore patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected. The investigators will determine whether this persistance varies according to - the severity of the Covid-19 - a treatment by steroids during the covid-19. This will help to anticipate whether a second wave of infection is possible in a non-naive population.
Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of
patients, neutralizing antibodies are detected. However, the long-term persistence of such
protective antibodies is not known.
The investigators will explore adult patients with a proven Covid-19 (positive PCR) 6 and 12
months after the diagnosis to determine whether neutralizing antibodies are still detected.
The investigators will determine whether this persistance varies according to
- the severity of the Covid-19 (3 groups: no oxyegn therapy; oxygen therapy of less than
3L/min; oxygen therapy of 3L/min or more)
- a treatment by steroids during the covid-19. Immunocompromised patients will be
excluded.
Diagnostic Test: serology
blood sample of 10 ml twice (6 and 12 months after the Covid-19)
Inclusion Criteria:
- positive SARS-CoV-2
Exclusion Criteria:
- age under 18
- immunocompromised at the onset of Covid-19
Olivier Epaulard, MD,PhD
0033476765291
oepaulard@chu-grenoble.fr
Olivier Epaulard, MD,PhD, Principal Investigator
University Hospital, Grenoble